ATE321063T1 - Neue immunoeffectorverbindungen - Google Patents
Neue immunoeffectorverbindungenInfo
- Publication number
- ATE321063T1 ATE321063T1 AT01959445T AT01959445T ATE321063T1 AT E321063 T1 ATE321063 T1 AT E321063T1 AT 01959445 T AT01959445 T AT 01959445T AT 01959445 T AT01959445 T AT 01959445T AT E321063 T1 ATE321063 T1 AT E321063T1
- Authority
- AT
- Austria
- Prior art keywords
- compounds
- new
- antigen
- present
- immunoeffector
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- SXSXOQFGUZXAEK-SXTMZTKSSA-N N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O.N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O.N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O SXSXOQFGUZXAEK-SXTMZTKSSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- DKVBOUDTNWVDEP-NJCHZNEYSA-N teicoplanin aglycone Chemical group N([C@H](C(N[C@@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)OC=1C=C3C=C(C=1O)OC1=CC=C(C=C1Cl)C[C@H](C(=O)N1)NC([C@H](N)C=4C=C(O5)C(O)=CC=4)=O)C(=O)[C@@H]2NC(=O)[C@@H]3NC(=O)[C@@H]1C1=CC5=CC(O)=C1 DKVBOUDTNWVDEP-NJCHZNEYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22305600P | 2000-08-04 | 2000-08-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE321063T1 true ATE321063T1 (de) | 2006-04-15 |
Family
ID=22834828
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01959445T ATE321063T1 (de) | 2000-08-04 | 2001-08-03 | Neue immunoeffectorverbindungen |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US7129219B2 (https=) |
| EP (1) | EP1311522B1 (https=) |
| JP (1) | JP4843181B2 (https=) |
| AT (1) | ATE321063T1 (https=) |
| AU (2) | AU8100101A (https=) |
| CA (1) | CA2417806C (https=) |
| DE (1) | DE60118207T2 (https=) |
| ES (1) | ES2261453T3 (https=) |
| WO (1) | WO2002012258A1 (https=) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1482795B1 (en) * | 2002-02-04 | 2009-11-11 | Corixa Corporation | New immunoeffector compounds |
| US6525028B1 (en) | 2002-02-04 | 2003-02-25 | Corixa Corporation | Immunoeffector compounds |
| JP2005523902A (ja) | 2002-02-04 | 2005-08-11 | コリクサ コーポレイション | 感染症及び他の疾患の免疫効果化合物による予防及び治療処理 |
| US6911434B2 (en) | 2002-02-04 | 2005-06-28 | Corixa Corporation | Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds |
| RU2340621C2 (ru) * | 2002-07-08 | 2008-12-10 | Корикса Корпорейшн | Способы получения аминоалкилглюкозаминидфосфатов и дисахаридных иммуноэффекторов и их промежуточных соединений |
| US7288640B2 (en) | 2002-07-08 | 2007-10-30 | Corixa Corporation | Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors, and intermediates therefor |
| US7960522B2 (en) | 2003-01-06 | 2011-06-14 | Corixa Corporation | Certain aminoalkyl glucosaminide phosphate compounds and their use |
| CA2512108C (en) | 2003-01-06 | 2013-04-02 | Corixa Corporation | Certain aminoalkyl glucosaminide phosphate compounds and their use |
| US7998930B2 (en) * | 2004-11-04 | 2011-08-16 | Hanall Biopharma Co., Ltd. | Modified growth hormones |
| PL1973564T3 (pl) | 2005-12-22 | 2017-04-28 | Glaxosmithkline Biologicals S.A. | Szczepionki zawierające koniugaty polisacharydu otoczkowego streptococcus pneumoniae |
| GB0607088D0 (en) | 2006-04-07 | 2006-05-17 | Glaxosmithkline Biolog Sa | Vaccine |
| SI2167121T1 (sl) | 2007-06-26 | 2015-12-31 | Glaxosmithkline Biologicals S.A. | Cepivo, ki obsega kapsularne polisaharidne konjugate Streptococcusa pneumoniae |
| EP2550362B1 (en) | 2010-03-25 | 2017-01-04 | Oregon Health&Science University | Cmv glycoproteins and recombinant vectors |
| GB201009273D0 (en) * | 2010-06-03 | 2010-07-21 | Glaxosmithkline Biolog Sa | Novel vaccine |
| GB201101331D0 (en) * | 2011-01-26 | 2011-03-09 | Glaxosmithkline Biolog Sa | Compositions and uses |
| CA2832109C (en) | 2011-06-10 | 2021-07-06 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
| GB201113570D0 (en) | 2011-08-05 | 2011-09-21 | Glaxosmithkline Biolog Sa | Vaccine |
| EP2568289A3 (en) | 2011-09-12 | 2013-04-03 | International AIDS Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies |
| US9402894B2 (en) | 2011-10-27 | 2016-08-02 | International Aids Vaccine Initiative | Viral particles derived from an enveloped virus |
| EP2679596B1 (en) | 2012-06-27 | 2017-04-12 | International Aids Vaccine Initiative | HIV-1 env glycoprotein variant |
| DE102012222886B4 (de) * | 2012-12-12 | 2014-11-27 | Jöst Gmbh | Genopptes Schleif- und Reinigungsvlies sowie Herstellung und Verwendung desselben |
| ES2743465T3 (es) | 2013-03-15 | 2020-02-19 | Glaxosmithkline Biologicals Sa | Composición que contiene derivados fosfato de aminoalquil glucosaminida tamponados y su uso para potenciar una respuesta inmunitaria |
| EP2848937A1 (en) | 2013-09-05 | 2015-03-18 | International Aids Vaccine Initiative | Methods of identifying novel HIV-1 immunogens |
| US10058604B2 (en) | 2013-10-07 | 2018-08-28 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
| KR20160132088A (ko) | 2014-03-12 | 2016-11-16 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 점막 전달용 리포솜 조성물 |
| KR20160127828A (ko) | 2014-03-12 | 2016-11-04 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 면역원성 리포솜 제형 |
| MA41414A (fr) | 2015-01-28 | 2017-12-05 | Centre Nat Rech Scient | Protéines de liaison agonistes d' icos |
| EP3069730A3 (en) | 2015-03-20 | 2017-03-15 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
| EP3072901A1 (en) | 2015-03-23 | 2016-09-28 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
| WO2017021912A1 (en) | 2015-08-06 | 2017-02-09 | Glaxosmithkline Intellectual Property Development Limited | Combined tlrs modulators with anti ox40 antibodies |
| TW201716084A (zh) | 2015-08-06 | 2017-05-16 | 葛蘭素史克智慧財產發展有限公司 | 組合物及其用途與治療 |
| EP3331565A1 (en) | 2015-08-06 | 2018-06-13 | GlaxoSmithKline Intellectual Property Development Ltd | Tlr4 agonists and compositions thereof and their use in the treatment of cancer |
| TWI704154B (zh) | 2015-12-03 | 2020-09-11 | 英商葛蘭素史克智慧財產發展有限公司 | 新穎化合物 |
| WO2017098421A1 (en) | 2015-12-08 | 2017-06-15 | Glaxosmithkline Intellectual Property Development Limited | Benzothiadiazine compounds |
| US11351237B2 (en) | 2015-12-22 | 2022-06-07 | Thomas Jefferson University | CMV-based intra-tumoral cancer therapies |
| WO2017153952A1 (en) | 2016-03-10 | 2017-09-14 | Glaxosmithkline Intellectual Property Development Limited | 5-sulfamoyl-2-hydroxybenzamide derivatives |
| JP2019510802A (ja) | 2016-04-07 | 2019-04-18 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | タンパク質調節物質として有用な複素環アミド |
| HRP20220936T1 (hr) | 2016-04-07 | 2022-10-28 | Glaxosmithkline Intellectual Property Development Limited | Heterociklički amidi korisni kao modulatori proteina |
| CA3023157A1 (en) | 2016-05-05 | 2017-11-09 | Glaxosmithkline Intellectual Property (No.2) Limited | Enhancer of zeste homolog 2 inhibitors |
| JP2019521166A (ja) | 2016-07-20 | 2019-07-25 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Ｐｅｒｋ阻害剤としてのイソキノリン誘導体 |
| KR20190090824A (ko) | 2016-12-01 | 2019-08-02 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 암을 치료하는 방법 |
| US11389465B2 (en) | 2017-05-01 | 2022-07-19 | Vanderbilt University | Phosphorylated hexaacyl disaccharides (PHADs) for treating or preventing infections |
| WO2019021208A1 (en) | 2017-07-27 | 2019-01-31 | Glaxosmithkline Intellectual Property Development Limited | USEFUL INDAZOLE DERIVATIVES AS PERK INHIBITORS |
| WO2019053617A1 (en) | 2017-09-12 | 2019-03-21 | Glaxosmithkline Intellectual Property Development Limited | CHEMICAL COMPOUNDS |
| CA3077337A1 (en) | 2017-10-05 | 2019-04-11 | Glaxosmithkline Intellectual Property Development Limited | Modulators of stimulator of interferon genes (sting) |
| US20210238172A1 (en) | 2017-10-05 | 2021-08-05 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides useful as protein modulators and methods of using the same |
| ES2985591T3 (es) | 2018-02-12 | 2024-11-06 | Inimmune Corp | Ligandos de receptores tipo Toll |
| GB201807924D0 (en) | 2018-05-16 | 2018-06-27 | Ctxt Pty Ltd | Compounds |
| WO2020030570A1 (en) | 2018-08-06 | 2020-02-13 | Glaxosmithkline Intellectual Property Development Limited | Combinations of an ox40 antibody and a tlr4 modulator and uses thereof |
| WO2020030571A1 (en) | 2018-08-06 | 2020-02-13 | Glaxosmithkline Intellectual Property Development Limited | Combinations of a pd-1 antibody and a tlr4 modulator and uses thereof |
| WO2020031087A1 (en) | 2018-08-06 | 2020-02-13 | Glaxosmithkline Intellectual Property Development Limited | Combination therapy |
| WO2020109365A1 (en) | 2018-11-29 | 2020-06-04 | Glaxosmithkline Biologicals Sa | Methods for manufacturing an adjuvant |
| JP2022533194A (ja) | 2019-05-16 | 2022-07-21 | スティングセラ インコーポレイテッド | ベンゾ［ｂ］［１，８］ナフチリジン酢酸誘導体および使用方法 |
| US20220227761A1 (en) | 2019-05-16 | 2022-07-21 | Stingthera, Inc. | Oxoacridinyl acetic acid derivatives and methods of use |
| KR20220026585A (ko) | 2019-06-26 | 2022-03-04 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Il1rap 결합 단백질 |
| GB201910304D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
| GB201910305D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
| KR20220035457A (ko) | 2019-07-21 | 2022-03-22 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 치료 바이러스 백신 |
| WO2021018941A1 (en) | 2019-07-31 | 2021-02-04 | Glaxosmithkline Intellectual Property Development Limited | Methods of treating cancer |
| WO2021043961A1 (en) | 2019-09-06 | 2021-03-11 | Glaxosmithkline Intellectual Property Development Limited | Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy |
| WO2021048081A1 (en) | 2019-09-09 | 2021-03-18 | Glaxosmithkline Biologicals Sa | Immunotherapeutic compositions |
| JP7280387B2 (ja) | 2019-09-27 | 2023-05-23 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | 抗原結合タンパク質 |
| CN114981265B (zh) | 2019-12-18 | 2025-01-03 | Ctxt私人有限公司 | 化合物 |
| US20230234992A1 (en) | 2020-06-05 | 2023-07-27 | Glaxosmithkline Biologicals Sa | Modified betacoronavirus spike proteins |
| EP4032547A1 (en) | 2021-01-20 | 2022-07-27 | GlaxoSmithKline Biologicals S.A. | Hsv1 fce derived fragements for the treatment of hsv |
| CN116917273A (zh) | 2021-03-02 | 2023-10-20 | 葛兰素史克知识产权发展有限公司 | 作为dnmt1抑制剂的经取代的吡啶 |
| JP2024511831A (ja) | 2021-03-31 | 2024-03-15 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | 抗原結合タンパク質およびそれらの組み合わせ |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6113918A (en) | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
| US6013640A (en) * | 1998-08-21 | 2000-01-11 | Ribi Immunochem Research, Inc. | Phosphoglycolipid and methods for its use |
| US6525028B1 (en) * | 2002-02-04 | 2003-02-25 | Corixa Corporation | Immunoeffector compounds |
| US6911434B2 (en) * | 2002-02-04 | 2005-06-28 | Corixa Corporation | Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds |
-
2001
- 2001-08-03 US US10/469,620 patent/US7129219B2/en not_active Expired - Lifetime
- 2001-08-03 WO PCT/US2001/024284 patent/WO2002012258A1/en not_active Ceased
- 2001-08-03 CA CA2417806A patent/CA2417806C/en not_active Expired - Lifetime
- 2001-08-03 ES ES01959445T patent/ES2261453T3/es not_active Expired - Lifetime
- 2001-08-03 AU AU8100101A patent/AU8100101A/xx active Pending
- 2001-08-03 EP EP01959445A patent/EP1311522B1/en not_active Expired - Lifetime
- 2001-08-03 DE DE60118207T patent/DE60118207T2/de not_active Expired - Lifetime
- 2001-08-03 AT AT01959445T patent/ATE321063T1/de not_active IP Right Cessation
- 2001-08-03 JP JP2002518232A patent/JP4843181B2/ja not_active Expired - Lifetime
- 2001-08-03 AU AU2001281001A patent/AU2001281001B2/en not_active Expired
-
2006
- 2006-09-11 US US11/519,275 patent/US7501399B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| US20040132988A1 (en) | 2004-07-08 |
| US20070004914A1 (en) | 2007-01-04 |
| CA2417806C (en) | 2011-05-10 |
| EP1311522A4 (en) | 2004-06-09 |
| US7129219B2 (en) | 2006-10-31 |
| AU2001281001B2 (en) | 2005-11-03 |
| DE60118207T2 (de) | 2006-11-09 |
| WO2002012258A1 (en) | 2002-02-14 |
| DE60118207D1 (de) | 2006-05-11 |
| EP1311522A1 (en) | 2003-05-21 |
| JP4843181B2 (ja) | 2011-12-21 |
| AU8100101A (en) | 2002-02-18 |
| EP1311522B1 (en) | 2006-03-22 |
| JP2004505986A (ja) | 2004-02-26 |
| CA2417806A1 (en) | 2002-02-14 |
| ES2261453T3 (es) | 2006-11-16 |
| US7501399B2 (en) | 2009-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE321063T1 (de) | Neue immunoeffectorverbindungen | |
| CY1109692T1 (el) | Νεες ανοσοδραστικες συνθεσεις | |
| TR200103018T2 (tr) | İmmünostimülatör oligonükleotid ve saponin içeren katkı bileşikleri. | |
| CY1118443T1 (el) | Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις | |
| ATA155598A (de) | Neue influenzavirus-impfstoffzusammensetzung | |
| CY1107628T1 (el) | Ανθρωπινα ctla-4 αντισωματα και χρησεις αυτων | |
| EA200300464A1 (ru) | ГУМАНИЗИРОВАННОЕ АНТИТЕЛО ПРОТИВ РЕЦЕПТОРА ЛИМФОТОКСИНА-β (ВАРИАНТЫ), КОМПОЗИЦИЯ, СПОСОБ ЛЕЧЕНИЯ ИЛИ СНИЖЕНИЯ РИСКА РАЗВИТИЯ, ТЯЖЕСТИ ИЛИ ПОСЛЕДСТВИЙ НЕОПЛАЗИИ У ЧЕЛОВЕКА, ВЫДЕЛЕННАЯ НУКЛЕИНОВАЯ КИСЛОТА (ВАРИАНТЫ), КЛЕТКА КЛЕТОЧНОЙ ЛИНИИ | |
| ATE382690T1 (de) | Modulierung der durch cpg-oligonukleotide verursachte immunstimulierung durch positionsbedingte veränderung von nukleosiden | |
| CY1112993T1 (el) | Παραγοντες ειδικης δεσμευσης της αγγειοποιητινης-2 και της αγγειοποιητινης-1 | |
| EA200400063A1 (ru) | Антитела к опг лиганду | |
| DE602004029904D1 (de) | Neue tricyclische nukleoside oder nukleotide als therapeutische mittel | |
| MXPA05014016A (es) | Proteinas portadoras para vacunas. | |
| TW200633719A (en) | Glycoconjugate vaccines containing peptidoglycan | |
| DE60121545D1 (de) | Virus des porzinen reproduktiven und respiratorischen syndroms und dessen verwendung | |
| BR9913446A (pt) | Produtos de aglicona e métodos de uso | |
| AU1922902A (en) | Novel means for the diagnosis and therapy of CTCL | |
| FI20011664A7 (fi) | Syöpäpesifiset oligoskkaridisekvenssit ja niiden käyttö | |
| FI20011671A7 (fi) | Tuumorispesifiset oligosakkaridisekvenssit ja niiden käyttö | |
| ES2196150T3 (es) | Induccion de tolerancia inmunologica por el uso de anticuerpos anti-cd4 que no inducen deplecion. | |
| BR0015872A (pt) | Agentes antitrombóticos | |
| BR0109164A (pt) | Anticorpos monoclonais para o receptor humano para ldl, produção e uso dos mesmos | |
| NO20022969L (no) | Sammensetninger og metoder for L-nukleosider, L-nukleotider og analoger derav | |
| DK0858465T3 (da) | Protein med antitumorvirkning. | |
| UA11507U (uk) | Спосіб лікування гострих кишкових інфекцій у дітей | |
| BR1100558A (pt) | famìlia de anticorpos modificados, com elevada afinidade, para tratamento de cáncer. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |